A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354
Sponsor: Cambridge Antibody Technology
Terminated
The study was terminated prematurely by the sponsor due to slow recruitment.
Other terminated trials from Cambridge Antibody Technology
More terminations from Cambridge Antibody Technology
Listed as NCT00640016, this PHASE2 trial focuses on Asthma and remains terminated or withdrawn. Sponsored by Cambridge Antibody Technology, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge Antibody Technology
- MedImmune LLC
- PRA Health Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Belfast, United Kingdom , Berlin, Germany , Bialystok, Poland , Birmingham, United Kingdom , Bonn, Germany , Box Hill, Australia , Clayton, Australia , Darlinghurst, Australia , Footscray, Australia and 25 more locations